Asston Pharmaceuticals Limited (BOM:544445)
India · Delayed Price · Currency is INR 83.80
-0.69 (-0.82%)
At close: Jan 19, 2026
Asston Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| 244.84 | 250.39 | 155.86 | 65.38 | 95.99 | 80.34 | Upgrade | |
Revenue Growth (YoY) | 274.49% | 60.65% | 138.39% | -31.89% | 19.47% | 221.60% | Upgrade |
Cost of Revenue | 132.52 | 141.44 | 97.54 | 33.49 | 76.74 | 53.12 | Upgrade |
Gross Profit | 112.33 | 108.96 | 58.32 | 31.89 | 19.25 | 27.22 | Upgrade |
Selling, General & Admin | 16.34 | 15.02 | 8.81 | 5.93 | 6.18 | 5.47 | Upgrade |
Other Operating Expenses | 32.33 | 29.98 | 16.61 | 10.79 | 16.62 | 19.15 | Upgrade |
Operating Expenses | 49.98 | 45.81 | 25.92 | 17.09 | 22.89 | 24.79 | Upgrade |
Operating Income | 62.35 | 63.14 | 32.4 | 14.8 | -3.64 | 2.43 | Upgrade |
Interest Expense | -6.54 | -7.98 | -9.01 | -6.76 | -4.25 | -0.81 | Upgrade |
Interest & Investment Income | 0.87 | 0.87 | 1.21 | 0.51 | 0 | - | Upgrade |
Currency Exchange Gain (Loss) | -2.36 | -2.36 | -7.45 | 5.11 | 7.45 | -0.01 | Upgrade |
Other Non Operating Income (Expenses) | 11.82 | 3.32 | 1.02 | 0.47 | 2.02 | -0.41 | Upgrade |
Pretax Income | 32.65 | 57 | 18.17 | 14.13 | 1.59 | 1.21 | Upgrade |
Income Tax Expense | 8.07 | 13.75 | 4.57 | 3.56 | 0.48 | 0.3 | Upgrade |
Net Income | 24.58 | 43.25 | 13.6 | 10.57 | 1.11 | 0.92 | Upgrade |
Net Income to Common | 24.58 | 43.25 | 13.6 | 10.57 | 1.11 | 0.92 | Upgrade |
Net Income Growth | 132.63% | 217.95% | 28.74% | 855.34% | 20.70% | 160.49% | Upgrade |
Shares Outstanding (Basic) | 7 | 6 | 6 | 6 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 7 | 6 | 6 | 6 | 0 | 0 | Upgrade |
Shares Change (YoY) | 16.68% | 11.99% | - | 5783.59% | 18.98% | - | Upgrade |
EPS (Basic) | 3.76 | 6.90 | 2.43 | 1.89 | 11.63 | 11.45 | Upgrade |
EPS (Diluted) | 3.76 | 6.90 | 2.37 | 1.89 | 11.62 | 11.45 | Upgrade |
EPS Growth | 99.37% | 191.00% | 25.61% | -83.76% | 1.45% | 160.49% | Upgrade |
Free Cash Flow | - | -1.63 | -38.11 | -5.67 | -11.89 | -16.62 | Upgrade |
Free Cash Flow Per Share | - | -0.26 | -6.80 | -1.01 | -124.88 | -207.77 | Upgrade |
Gross Margin | 45.88% | 43.51% | 37.42% | 48.77% | 20.05% | 33.88% | Upgrade |
Operating Margin | 25.46% | 25.22% | 20.79% | 22.63% | -3.79% | 3.03% | Upgrade |
Profit Margin | 10.04% | 17.27% | 8.73% | 16.16% | 1.15% | 1.14% | Upgrade |
Free Cash Flow Margin | - | -0.65% | -24.45% | -8.67% | -12.38% | -20.69% | Upgrade |
EBITDA | 63.6 | 63.95 | 32.9 | 15.17 | -3.55 | 2.6 | Upgrade |
EBITDA Margin | 25.97% | 25.54% | 21.11% | 23.20% | -3.70% | 3.24% | Upgrade |
D&A For EBITDA | 1.25 | 0.81 | 0.51 | 0.37 | 0.08 | 0.17 | Upgrade |
EBIT | 62.35 | 63.14 | 32.4 | 14.8 | -3.64 | 2.43 | Upgrade |
EBIT Margin | 25.46% | 25.22% | 20.79% | 22.63% | -3.79% | 3.03% | Upgrade |
Effective Tax Rate | 24.72% | 24.12% | 25.14% | 25.20% | 30.40% | 24.56% | Upgrade |
Revenue as Reported | 259.05 | 256.1 | 158.41 | 71.92 | 105.55 | 81.26 | Upgrade |
Advertising Expenses | - | - | - | - | - | 0.86 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.